eLAS Suite

The eLAS® Suite, developed by Clinical ink, is a fit-for-purpose Electronic Lupus Assessment Suite designed to simplify, streamline, and standardize data collection in Systemic Lupus Erythematosus (SLE) clinical trials. Built on eSource and Direct Data Capture (DDC) technology, eLAS® is purpose-built for the unique complexities of lupus research, making it an essential tool for clinical research sites, study teams, and sponsors conducting SLE studies.

SLE clinical trials are inherently complex. Lupus affects individuals differently, presenting a wide range of symptoms that vary in severity. Research has historically relied on multiple questionnaires — each with distinct scoring systems — leading to confusion, inconsistency, duplicative data entry, and reduced patient participation. Clinical ink developed eLAS® to directly address these challenges by integrating the most widely used SLE diagnostic questionnaires into a single, intuitive platform that is applied during the patient visit, ensuring that when the visit is complete, so is the documentation.

Core Capabilities of eLAS®

• Integrates the most commonly used SLE assessment tools, including BILAG (British Isles Lupus Assessment Group), SLEDAI (Systemic Lupus Erythematosus Disease Activity Index), and CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index)
• Leverages Direct Data Capture (DDC) technology to enable information sharing between forms and reduce duplicative data entry
• Displays contextual prompts that clarify the proper evaluation methods for each specific questionnaire
• Provides an intuitive interface designed to be used directly during the patient visit
• Displays data from previous visits to support continuity and informed clinical assessment
• Supports data capture both online and offline, ensuring flexibility across site environments
• Connects structured and unstructured supporting data for a comprehensive view of each patient
• Validates data at the point of capture to improve accuracy and reduce downstream corrections
• Enables data corrections during patient visits, supporting real-time quality management

Workflow and Study Management Benefits

• Pre-programmed workflows and study processes reduce site burden and administrative overhead
• Reduces overall workload for clinical site staff while improving data quality
• Enables immediate sharing of data and reports across the entire study team
• Optimizes decision-making by providing timely, reliable, and connected data
• Engages patients through a straightforward and efficient data capture experience

SLE Assessments Supported

• BILAG: Assesses disease activity across different organ systems
• SLEDAI: Measures SLE disease activity by evaluating a combination of symptoms and laboratory results
• CLASI: Targets assessment of skin-related lupus symptoms specifically
• SLICC/ACR: A damage index evaluating accumulated damage across organ systems not attributed to active lupus inflammation
• Patient-Reported Outcomes (PROs): Self-reported questionnaires capturing the patient's perspective on symptoms, functional status, and overall well-being

The Purpose of Lupus Clinical Trials

• Test new treatments, therapies, and interventions to advance medical knowledge about lupus
• Identify more effective and safer ways to manage lupus symptoms and reduce disease flares
• Improve patients' quality of life and work toward discovering a lupus cure
• Follow strict scientific guidelines and protocols, with careful monitoring of participants and rigorous collection and analysis of health data

eLAS® is deployed as part of Clinical ink's broader eSource technology platform, which also encompasses eCOA, eConsent, patient engagement, telehealth, and sensor and wearable integrations. By setting the standard for data collection in lupus research, eLAS® helps sponsors and sites conduct SLE trials that are more efficient, more reliable, and better positioned to generate high-quality evidence.